14-day Premium Trial Subscription Try For FreeTry Free
Goldman Sachs Group Inc. lifted its stake in shares of ConforMIS Inc (NASDAQ:CFMS) by 261.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commiss

Cambridge biotech to return its PPP loan

11:01pm, Thursday, 23'rd Apr 2020
Wave Life Sciences is testing a synthetic nucleic acid therapy that it believes can correct Duchenne muscular dystrophy patients' inability to product a protein linked to muscle development.
Conformis, Inc. (CFMS) announced today that, due in large part to a loan made available to the Company under the Paycheck Protection Program (“PPP Loan”) offered by the U.S. Small Business Adminis
Brokerages expect ConforMIS Inc (NASDAQ:CFMS) to announce ($0.09) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for ConforMIS’s earnings, wit
Wall Street analysts expect ConforMIS Inc (NASDAQ:CFMS) to announce sales of $18.95 million for the current quarter, Zacks reports. Two analysts have issued estimates for ConforMIS’s earnings, with
Conformis, Inc. (CFMS) today announced that on April 17, 2020 the Company entered into a $4,719,800 promissory note with East West Bank (EWBC) under the Paycheck Protection Program (“PPP”) offered
ConforMIS Inc (NASDAQ:CFMS) has earned an average recommendation of “Hold” from the six brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated th
Conformis, Inc. (CFMS) today announced that, due to the public health impact of the novel coronavirus outbreak and governmental restrictions limiting the number of people who may gather together, and
Zacks.com featured highlights include: Amphastar Pharmaceuticals, ConforMIS, Kirkland Lake Gold, Cubic and Cimpress

ConforMIS (CFMS) Gets a Hold Rating from BTIG

05:27pm, Tuesday, 24'th Mar 2020
BTIG analyst Ryan Zimmerman maintained a Hold rating on ConforMIS (CFMS – Research Report) yesterday. The company’s shares closed last
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Oppenheimer analyst Steven Lichtman maintained a Buy rating on ConforMIS (CFMS – Research Report) today. The company’s shares closed last
Conformis, Inc. (CFMS), an orthopedic arthroplasty medical technology company, today announced proactive steps it is taking and planning to mitigate the negative financial and operational impacts of t
Q4 2019 Conformis Inc Earnings Call
Oppenheimer analyst Steven Lichtman maintained a Buy rating on ConforMIS (CFMS – Research Report) today and set a price target
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE